SCHEMBL3007799

SCHEMBL3007799

Cc1ccc(C)c(Cc2csc(N3CCN(S(=O)(=O)c4ccccc4Cl)CC3)n2)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 2/20 0.42
TP53 P04637 1/20 0.42
CHRM4 P08173 6/20 0.41
MEN1 O00255 2/20 0.41
LMNA P02545 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPK1 P28482 1/20 0.41
GBA1 P04062 3/20 0.40
CHRM2 P08172 1/20 0.39
CHRM5 P08912 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
FAAH O00519 1/20 0.39
EPHX2 P34913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3010503 0.93 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2RAB9AL3MBTL1MAPT
SCHEMBL3014116 0.91 MAPT (0.44) ALDH1A1SMN1; SMN2RAB9AL3MBTL1MAPT
SCHEMBL3015983 0.91 LPAR1 (0.42) ALDH1A1SMN1; SMN2RAB9AL3MBTL1MAPT
SCHEMBL3014221 0.90 CHRM4 (0.44) ALDH1A1SMN1; SMN2RAB9AMAPTTP53
SCHEMBL3008380 0.90 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2RAB9AL3MBTL1MAPT
SCHEMBL3002483 0.89 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2RAB9AL3MBTL1MAPT
SCHEMBL3007657 0.88 SMN1; SMN2 (0.41) ALDH1A1SMN1; SMN2RAB9AL3MBTL1MAPT
SCHEMBL3022709 0.88 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2RAB9AL3MBTL1MAPT
SCHEMBL3017190 0.87 KMT2A (0.47) ALDH1A1SMN1; SMN2RAB9AL3MBTL1MAPT
SCHEMBL3014732 0.87 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2RAB9AL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.